Summary
22.46 0.08(0.36%)07/01/2024
Intellia Therapeutics Inc (NTLA)
Intellia Therapeutics Inc (NTLA)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.40 | -10.12 | -4.38 | -17.54 | -27.05 | -44.83 | 36.70 | 1.63 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 22.46 | |
| Open | 22.11 | |
| High | 23.43 | |
| Low | 22.08 | |
| Volume | 1,038,945 | |
| Change | 0.09 | |
| Change % | 0.40 | |
| Avg Volume (20 Days) | 1,393,974 | |
| Volume/Avg Volume (20 Days) Ratio | 0.75 | |
| 52 Week Range | 19.37 - 46.50 | |
| Price vs 52 Week High | -51.70% | |
| Price vs 52 Week Low | 15.95% | |
| Range | 1.58 | |
| Gap Up/Down | -1.08 | |
Fundamentals | ||
| Market Capitalization (Mln) | 2,168 | |
| EBIDTA | -91,114,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 174.56 | |
| Book Value | 14.8920 | |
| Earnings Per Share | -3.3850 | |
| EPS Estimate Current Quarter | -0.8200 | |
| EPS Estimate Next Quarter | -0.7700 | |
| EPS Estimate Current Year | -3.6400 | |
| EPS Estimate Next Year | -3.8500 | |
| Diluted EPS (TTM) | -3.3850 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -8.5778 | |
| Return on asset (TTM) | -0.1602 | |
| Return on equity (TTM) | -0.3186 | |
| Revenue TTM | 26,794,000 | |
| Revenue per share TTM | 0.3960 | |
| Quarterly Revenue Growth (YOY) | -0.6760 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -92,414,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 7.6638 | |
| Revenue Enterprise Value | 289.7017 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 74,419,400 | |
| Shares Float | 67,244,638 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 10.05 | |
| Institutions (%) | 83.58 | |
06/28 10:28 EST - investorplace.com
Treasure Hunt: 3 Biotech Stocks Wall Street Hasn't Discovered Yet
Searching for quality undiscovered biotech stocks can be a bit like a treasure hunt. The biotech scene is full of intriguing innovators trying to progress their treatments through various clinical trials.
Treasure Hunt: 3 Biotech Stocks Wall Street Hasn't Discovered Yet
Searching for quality undiscovered biotech stocks can be a bit like a treasure hunt. The biotech scene is full of intriguing innovators trying to progress their treatments through various clinical trials.
06/27 22:02 EST - investorplace.com
You've Been Warned! 3 Gene Editing Stocks to Buy Now or Regret Forever.
With the progression of modern medicine, and the continuous discoveries in the realm of gene editing, investing early in the technology could be a game changer for long-term returns if selecting the best gene editing stocks to buy. That's because unlike more standard therapeutics such as antibiotics, antivirals and vaccines gene editing is a permanent solution most of the time.
You've Been Warned! 3 Gene Editing Stocks to Buy Now or Regret Forever.
With the progression of modern medicine, and the continuous discoveries in the realm of gene editing, investing early in the technology could be a game changer for long-term returns if selecting the best gene editing stocks to buy. That's because unlike more standard therapeutics such as antibiotics, antivirals and vaccines gene editing is a permanent solution most of the time.
06/27 16:48 EST - seekingalpha.com
3 Biotech Stocks For The Second Half Of 2024
3 Biotech Stocks For The Second Half Of 2024
3 Biotech Stocks For The Second Half Of 2024
3 Biotech Stocks For The Second Half Of 2024
06/27 11:40 EST - zacks.com
Intellia (NTLA) Shares Fall as CFO Glenn Goddard Steps Down
Intellia (NTLA) appoints Edward Dulac as its new chief financial officer after Glenn Goddard steps down from his role with effect from Jun 30.
Intellia (NTLA) Shares Fall as CFO Glenn Goddard Steps Down
Intellia (NTLA) appoints Edward Dulac as its new chief financial officer after Glenn Goddard steps down from his role with effect from Jun 30.
06/26 21:33 EST - investorplace.com
Rags to Riches: 3 Gene Editing Stocks That Could Make Early Investors Rich
Gene editing is a game-changer. With it, we can remove cells from your body, edit them, and then reintroduce them back into the body.
Rags to Riches: 3 Gene Editing Stocks That Could Make Early Investors Rich
Gene editing is a game-changer. With it, we can remove cells from your body, edit them, and then reintroduce them back into the body.
06/26 07:30 EST - globenewswire.com
Intellia Therapeutics Announces CFO Transition
CAMBRIDGE, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the appointment of Edward Dulac as Executive Vice President, Chief Financial Officer (CFO), and Treasurer, effective July 22, 2024. Mr. Dulac will succeed Glenn Goddard who will step down from his role effective June 30, 2024.
Intellia Therapeutics Announces CFO Transition
CAMBRIDGE, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the appointment of Edward Dulac as Executive Vice President, Chief Financial Officer (CFO), and Treasurer, effective July 22, 2024. Mr. Dulac will succeed Glenn Goddard who will step down from his role effective June 30, 2024.
06/25 15:30 EST - globenewswire.com
Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform
CAMBRIDGE, Mass., June 25, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today presented new data demonstrating for the first time the potential for redosing with an investigational, in vivo CRISPR/Cas9 genome editing therapy. These data from the ongoing Phase 1 study of NTLA-2001, a single-dose treatment in development for transthyretin (ATTR) amyloidosis, were presented at the Peripheral Nerve Society Annual Meeting, taking place June 22–25 in Montreal, Canada.
Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform
CAMBRIDGE, Mass., June 25, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today presented new data demonstrating for the first time the potential for redosing with an investigational, in vivo CRISPR/Cas9 genome editing therapy. These data from the ongoing Phase 1 study of NTLA-2001, a single-dose treatment in development for transthyretin (ATTR) amyloidosis, were presented at the Peripheral Nerve Society Annual Meeting, taking place June 22–25 in Montreal, Canada.
06/25 08:00 EST - investorplace.com
3 Gene Editing Stocks That Could Make Your Grandchildren Rich
Gene-editing stocks has been gaining substantial attention, as the industry holds the potential to revolutionize medicine. From curing genetic disorders to enhancing agricultural productivity, the applications are vast and transformative.
3 Gene Editing Stocks That Could Make Your Grandchildren Rich
Gene-editing stocks has been gaining substantial attention, as the industry holds the potential to revolutionize medicine. From curing genetic disorders to enhancing agricultural productivity, the applications are vast and transformative.
06/24 04:51 EST - benzinga.com
5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More
Biotech stocks are high-risk, high-return opportunities that are under the mercy of several make-or-break catalysts, most of which are binary events. It pays to remain cognizant of the timing of these catalysts and which way they will likely pan out.
5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More
Biotech stocks are high-risk, high-return opportunities that are under the mercy of several make-or-break catalysts, most of which are binary events. It pays to remain cognizant of the timing of these catalysts and which way they will likely pan out.
06/21 06:30 EST - investorplace.com
Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for June 2024
Investors looking for long-term returns should consider investing in strong buy Cathie Wood stocks this month. The ARK Invest Chief Executive Officer (CEO) gained a massive following in 2020 after all six of her exchange traded funds (ETFs) saw returns above 100%.
Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for June 2024
Investors looking for long-term returns should consider investing in strong buy Cathie Wood stocks this month. The ARK Invest Chief Executive Officer (CEO) gained a massive following in 2020 after all six of her exchange traded funds (ETFs) saw returns above 100%.
06/17 07:30 EST - globenewswire.com
Intellia Therapeutics to Present the First-Ever Clinical Data From Patients Redosed with an Investigational In Vivo CRISPR Gene Editing Therapy at the Peripheral Nerve Society Annual Meeting 2024
- Data to offer insight into the safety and pharmacodynamics of redosing patients with a systemically delivered LNP-based CRISPR gene editing candidate - Data to offer insight into the safety and pharmacodynamics of redosing patients with a systemically delivered LNP-based CRISPR gene editing candidate
Intellia Therapeutics to Present the First-Ever Clinical Data From Patients Redosed with an Investigational In Vivo CRISPR Gene Editing Therapy at the Peripheral Nerve Society Annual Meeting 2024
- Data to offer insight into the safety and pharmacodynamics of redosing patients with a systemically delivered LNP-based CRISPR gene editing candidate - Data to offer insight into the safety and pharmacodynamics of redosing patients with a systemically delivered LNP-based CRISPR gene editing candidate
06/14 12:50 EST - zacks.com
Intellia (NTLA) Banks on Genome Editing Pipeline Amid Rivalry
Intellia's (NTLA) lead genome-editing candidate, NTLA-2001 being developed to treat transthyretin (ATTR) amyloidosis, holds promise. Other pipeline candidates are also progressing well.
Intellia (NTLA) Banks on Genome Editing Pipeline Amid Rivalry
Intellia's (NTLA) lead genome-editing candidate, NTLA-2001 being developed to treat transthyretin (ATTR) amyloidosis, holds promise. Other pipeline candidates are also progressing well.
06/14 07:30 EST - globenewswire.com
Intellia Therapeutics Names Brian Goff to its Board of Directors
CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the appointment of Brian Goff to its board of directors.
Intellia Therapeutics Names Brian Goff to its Board of Directors
CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the appointment of Brian Goff to its board of directors.
06/09 06:20 EST - fool.com
Cathie Wood Goes Bargain Hunting: 2 Stocks She Just Bought
Cathie Wood loves bargains on potential long-term winners -- especially when the company is an innovator. One of her favorite technologies in healthcare is gene editing, and she's been loading up on two stocks in particular.
Cathie Wood Goes Bargain Hunting: 2 Stocks She Just Bought
Cathie Wood loves bargains on potential long-term winners -- especially when the company is an innovator. One of her favorite technologies in healthcare is gene editing, and she's been loading up on two stocks in particular.
06/08 07:25 EST - fool.com
These 2 Words Are Why Intellia Therapeutics Could Be a Smart Buy Right Now
Intellia Therapeutics has a gene editing therapy that looks to be quite effective. That's favorable for the program's chances of getting approved.
These 2 Words Are Why Intellia Therapeutics Could Be a Smart Buy Right Now
Intellia Therapeutics has a gene editing therapy that looks to be quite effective. That's favorable for the program's chances of getting approved.
06/06 11:05 EST - fool.com
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Wood added to her positions in Reddit, Intellia Therapeutics, and PagerDuty on Wednesday. Wood's Ark Invest was a buyer of Reddit the day it went public in March.
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Wood added to her positions in Reddit, Intellia Therapeutics, and PagerDuty on Wednesday. Wood's Ark Invest was a buyer of Reddit the day it went public in March.
06/05 13:35 EST - investorplace.com
The 3 Best Biotech Stocks to Buy in June 2024
The biotech sector, under the life sciences umbrella, exited 2023 with 41 bankruptcies. This was not surprising given the disparity between biotech's high-capital requirements and rising interest rates set by the Fed.
The 3 Best Biotech Stocks to Buy in June 2024
The biotech sector, under the life sciences umbrella, exited 2023 with 41 bankruptcies. This was not surprising given the disparity between biotech's high-capital requirements and rising interest rates set by the Fed.
06/05 07:11 EST - seekingalpha.com
Intellia Therapeutics Presents Promising In Vivo CRISPR Results
Intellia Therapeutics has released positive data from its Phase I/II study of NTLA-2002, a CRISPR-based gene editing therapy. The study shows promising results for in vivo gene editing, offering potential treatments for genetic diseases. Robust target engagement and efficacy data pave the way for future Phase II results from Intellia later this year.
Intellia Therapeutics Presents Promising In Vivo CRISPR Results
Intellia Therapeutics has released positive data from its Phase I/II study of NTLA-2002, a CRISPR-based gene editing therapy. The study shows promising results for in vivo gene editing, offering potential treatments for genetic diseases. Robust target engagement and efficacy data pave the way for future Phase II results from Intellia later this year.
06/04 12:25 EST - zacks.com
Intellia (NTLA) Up on Upbeat Long-Term Angioedema Study Data
Intellia (NTLA) gains 10% after reporting encouraging long-term efficacy data from the phase I portion of its early to mid-stage study evaluating NTLA-2002 for treating hereditary angioedema.
Intellia (NTLA) Up on Upbeat Long-Term Angioedema Study Data
Intellia (NTLA) gains 10% after reporting encouraging long-term efficacy data from the phase I portion of its early to mid-stage study evaluating NTLA-2002 for treating hereditary angioedema.
06/04 06:45 EST - fool.com
Cathie Wood Is Buying the Dip on These 2 Biotech Stocks. Should You?
Buying the dip in a promising stock can be an effective strategy. CRISPR Therapeutics has a long way to go before becoming profitable.
Cathie Wood Is Buying the Dip on These 2 Biotech Stocks. Should You?
Buying the dip in a promising stock can be an effective strategy. CRISPR Therapeutics has a long way to go before becoming profitable.